Last weekend, Pfizer
The duo said yesterday that they were stopping a trial testing apixaban in patients with atrial fibrillation, a type of irregular heartbeat, because it was clear that the drug worked better than aspirin at reducing strokes and blood clots. They're saving the full data for a medical presentation, but you can bet that the results will be substantially positive because the trial was stopped early.
Passing the trial is certainly a positive for Pfizer and Bristol, but the true test for apixaban is still to come. Yesterday's results were for a trial testing patients who couldn't take warfarin, a common drug used to treat prevent blood clots, but the largest market will be in patients who can take warfarin. The two companies are running a trial testing apixaban against warfarin, which should wrap up next year -- assuming it doesn't get stopped early as well.
Unlike other drugs that have tried to go after large indications but failed -- Eli Lilly's
Pfizer and Bristol-Myers aren't the only one to notice the need for a new drug. Bayer and Johnson & Johnson
Until then, coagulate in the comments and discuss the possibilities.
Pfizer is a Motley Fool Inside Value recommendation. Johnson & Johnson is an Income Investor pick and Motley Fool Options has recommended buying calls on the shares. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
The big drugmaker had a clear message at the J.P. Morgan Healthcare Conference -- and it's a good one for investors.
3 Scorching-Hot Healthcare Stocks -- Are They Buys?
These three companies gained at least 400% in 2017. Can the good times continue?